Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights

– R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19

Q3 2020 sales of $3,476,000 compared to $2,908,000 for Q3 2019, representing a 20% increase –

– Net profit of $192,000 for Q3 2020 vs. net loss of $104,000 for Q3 2019 –

Cash generated from operations of $4,777,000 in 2020 vs. $1,321,000 in 2019

Maintained production operations during COVID-19 pandemic and completed integration of manufacturing sites

EDMONTON, Alberta, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and the first nine months ended September 30, 2020.

“Over the course of the third quarter, our operations executed and adapted well, delivering significantly improved year over year results even during the final phase of integration of the production operations and despite the COVID-19 pandemic situation. We successfully completed the full integration of manufacturing operations under one roof in Edmonton, resumed the clinical trial for beta glucan as a cholesterol reducer, as well as the development and optimization of new products developed through the use of our PGX disruptive technology. Additionally, we are extremely proud of our employees who worked tirelessly since the beginning of the year to maintain operations and deliver these solid results despite the COVID-19 pandemic. As we continue to move forward, our focus remains on the health and safety of our associates, followed by business continuity,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.

Corporate and Operational Highlights

Pipeline Development:

  • Announced publication of positive results from study evaluating avenanthramides in exercise-induced inflammation in the international, peer-reviewed Journal of the International Society of Sports Nutrition.
  • Achieved the first milestones in successful development of PGX-processed yeast beta glucan product as a potential inhalable therapeutic for COVID-19 and other fibrotic endpoint diseases of the lung.
  • Confirmed capability of PGX Technology to optimize and standardize the size and morphology of yeast beta-glucan (PGX-YBG) suitable for lung inhalation.
  • Conducted in-vitro study with human cell lines demonstrating that PGX-YBG obtained from different sources exhibited significant stimulatory effect on human immune response through activation of beta glucan specific Dectin 1 receptors.
  • Ongoing PGX-YBG project with McMaster University conducted in parallel for naïve and preclinical animal models. To-date, no safety issues have been encountered. The preclinical phase has been extended to identify the maximum tolerated dose. Progress update on this exciting project to be issued in the near future.
  • Conducting additional in vitro PGX-YBG dose response study to correlate with upcoming McMaster animal study results.
  • Resumed enrollment of patients for the clinical trial with beta glucan as a cholesterol reducing natural pharmaceutical product. 191 patients have been screened and 65 randomized during the last three months.
  • Pursued the development of new PGX-dried chemical complexes for potential applications under various forms like pills, capsules, fast dissolving strips and face masks. Yeast beta glucan to become a key product of Ceapro’s portfolio.


  • Made significant technical upgrades of PGX demo plant to allow production of yeast beta glucan for a potential human clinical trial with COVID-19.
  • Acquired pieces of equipment suitable for the assembling of a commercial scale PGX unit. Timelines to initiate building of the customized large scale unit to be defined due to COVID-19 travel restrictions and resulting availability of expert personnel.
  • Initiated installment of a commercial scale unit for impregnation of bioactives with PGX-processed biopolymers.
  • Pursued research collaboration projects with University of Alberta and McMaster University for the impregnation of various bioactives using PGX-processed biopolymers as potential delivery systems for multiple applications in healthcare.

Production Operations:

  • Completed the decommissioning of Leduc manufacturing site and the moving of all production operations to the Edmonton based facility.


  • Fully repaid loan with Alberta Financial Service Corporation.
  • Advanced conversations with interested potential partners to utilize Ceapro’s innovative technologies.
  • Pursued out-licensing discussions for PGX-processed new chemical complexes.

Subsequent to Quarter:

  • Announced expansion of a grant from National Research Council of Canada for the optimization and mass production of yeast beta glucan as a potential inhalable therapeutic for COVID-19 and other fibrotic end-point disease of the lung.

Financial Highlights for the Third Quarter and Nine-Month Period Ended September 30, 2020

  • Total sales of $3,476,000 for the third quarter of 2020 and $12,415,000 for the first nine months of 2020 compared to $2,908,000 and $9,159,000 for the comparative periods in 2019. The 36% increase in sales for the first nine months is mainly due to a significant increase in sales of avenanthramides in the USA compared to the same period in 2019.
  • Net profit of $192,000 for the third quarter of 2020 and $2,395,000 for the first nine months of 2020 compared to a net loss of $104,000 and $1,299,000 for the comparative periods in 2019. An improvement of $3,694,000 for the nine-month period.
  • Excluding non-cash items, mainly amortization, adjusted net profit for the first nine months in 2020 is $ 4,035,000 versus adjusted net profit of $414,000 for the first nine months of 2019.
  • Cash flows generated from operations of $4,777,000 in 2020 vs $1,321,000 in 2019.
  • Positive working capital balance of $8,151,000 as of September 30, 2020.

“Looking ahead, while taking into account the ongoing potential economic impact related to COVID-19 and evolving consumption trends, we believe Ceapro is well-positioned to once again deliver a double-digit growth in sales well in line with the positive trend achieved over the last years. With a strong balance sheet, a group of dedicated people, and a solid base business, coupled with the innovative technologies and products that we have developed to enable us to expand, Ceapro is poised to emerge as a successful life science company,” concluded Mr. Gagnon.

Consolidated Balance Sheets      
  September 30, December 31,  
  2020 2019  
  $ $  
Current Assets      
Cash and cash equivalents 6,118,403 1,857,195  
Trade receivables 1,838,092 3,659,541  
Other receivables 143,187 46,812  
Inventories (note 3) 1,191,675 669,005  
Prepaid expenses and deposits 166,437 178,908  
  9,457,794 6,411,461  
Non-Current Assets      
Investment tax credits receivable 607,700 607,700  
Deposits 85,755 85,755  
Licences (note 4) 19,255 21,477  
Property and equipment (note 5) 18,605,763 19,764,122  
Deferred tax assets 378,643 378,643  
  19,697,116 20,857,697  
TOTAL ASSETS 29,154,910 27,269,158  
Current Liabilities      
Accounts payable and accrued liabilities 949,813 1,291,204  
Current portion of long-term debt (note 6) - 111,865  
Current portion of lease liabilities (note 7) 275,726 265,123  
Current portion of CAAP loan (note 9) 80,814 72,942  
  1,306,353 1,741,134  
Non-Current Liabilities      
Long-term lease liabilities (note 7) 2,567,487 2,775,627  
CAAP loan (note 9) 69,621 61,580  
Deferred tax liabilities 378,643 378,643  
  3,015,751 3,215,850  
TOTAL LIABILITIES 4,322,104 4,956,984  
Share capital (note 8 (b)) 16,507,998 16,401,677  
Contributed surplus (note 8 (e)) 4,669,684 4,650,090  
Retained earnings 3,655,124 1,260,407  
  24,832,806 22,312,174  
TOTAL LIABILITIES AND EQUITY 29,154,910 27,269,158  

CEAPRO INC.          
Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)  
  Quarters   Nine Months    
  Ended September 30,   Ended September 30,    
  2020   2019   2020   2019    
  $   $   $   $    
Revenue (note 15) 3,475,625   2,907,980   12,414,970   9,158,637    
Cost of goods sold 1,814,080   1,894,570   5,794,573   5,327,161    
Gross margin 1,661,545   1,013,410   6,620,397   3,831,476    
Research and product development 478,993   307,477   1,381,332   1,919,875    
General and administration 791,217   666,640   2,494,514   2,278,279    
Sales and marketing 12,395   87,176   89,830   289,956    
Finance costs (note 12) 43,066   51,865   189,258   213,052    
Income (loss) from operations 335,874   (99,748 ) 2,465,463   (869,686 )  
Other income (expenses) (note 11) (144,251 ) (3,766 ) (70,746 ) (429,047 )  
Income (loss) before tax 191,623   (103,514 ) 2,394,717   (1,298,733 )  
Income taxes -   -   -   -    
Total comprehensive income (loss) for the period 191,623   (103,514 ) 2,394,717   (1,298,733 )  
Net income (loss) per common share (note 18):          
Basic 0.00   (0.00 ) 0.03   (0.02 )  
Diluted 0.00   (0.00 ) 0.03   (0.02 )  
Weighted average number of common shares outstanding (note 18):          
Basic 77,610,113   77,313,015   77,585,679   77,138,854    
Diluted 78,700,415   77,313,015   78,039,105   77,138,854    

Consolidated Statements of Cash Flows      
  2020   2019    
Nine Months Ended September 30, $   $    
Net income (loss) for the period 2,394,717   (1,298,733 )  
Adjustments for items not involving cash      
Finance costs 117,237   132,161    
Transaction costs 1,108   3,633    
Depreciation and amortization 1,382,838   1,369,653    
Foreign exchange gain on long-term debt -   (307 )  
Accretion 15,913   22,258    
Share-based payments 122,902   185,557    
Net income (loss) for the period adjusted for non-cash items 4,034,715   414,222    
Trade receivables 1,821,449   705,254    
Other receivables (96,375 ) (16,754 )  
Inventories (522,670 ) (258,444 )  
Prepaid expenses and deposits 12,471   257,010    
Accounts payable and accrued liabilities relating to operating activities (355,552 ) 351,547    
Total changes in non-cash working capital items 859,323   1,038,613    
Net income (loss) for the period adjusted for non-cash and working capital items 4,894,038   1,452,835    
Interest paid (117,237 ) (132,161 )  
CASH GENERATED FROM OPERATIONS 4,776,801   1,320,674    
Purchase of property and equipment (222,610 ) (338,548 )  
Proceeds from sale of equipment 353   -    
Deposits relating to investment in equipment -   187,790    
Accounts payable and accrued liabilities relating to investing activities 14,161   54,933    
Stock options exercised 3,013   17,284    
Repayment of long-term debt (112,973 ) (288,617 )  
Repayment of lease liabilities (197,537 ) (201,850 )  
Increase in cash and cash equivalents 4,261,208   751,666    
Cash and cash equivalents at beginning of the period 1,857,195   1,844,134    
Cash and cash equivalents at end of the period 6,118,403   2,595,800    

The complete financial statements are available for review on SEDAR at https://sedar.com/Ceapro and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

This press release does not express or imply that the Company claims its product has the ability to eliminate, cure or contain the SARS-2-CoV-2 (COVID-19) at this time.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Primary Logo

Source: Ceapro Inc.